Feedback
Settings

Settings

Goto Application

222,717 results
Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C12Q1/68

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 22,272
1.WO/2021/009317EXTRACELLULAR VESICLES CONTAINING MIR-142-3P TO TREAT FIBROSING DISEASES
WO - 21.01.2021
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
 Appl.No PCT/EP2020/070215 Applicant UNIVERSITÉ DE LIÈGE Inventor GUIOT, Julien
The present invention relates to pharmaceutical formulations comprising extracellular vesicles wherein the content of the vesicles comprises microRNA miR-142-3p, methods for producing the pharmaceutical formulations, and uses of the formulations to treat fibro-inflammatory diseases in a subject.
2.WO/2021/010442PROTEIN AND RNA INTERACTION EVALUATION METHOD, INTERACTION MODULATOR EVALUATION METHOD AND INTERACTION MODULATOR DETECTION METHOD, AND FUSION PROTEIN, KIT AND BIOSENSOR USING SAME
WO - 21.01.2021
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/JP2020/027710 Applicant THE UNIVERSITY OF TOKYO Inventor ENDO Kei
Provided is a method for evaluating the interaction of a protein and RNA, said method comprising: (1) a step for bringing the following (a), (b), and (c) into contact in cytoplasm or a cell-free system, in which (a) is a first fusion protein obtained by fusing a subject protein and a first element of a marker protein, (b) is a second fusion protein obtained by fusing an RNA binding protein and a second element of the marker protein, and (c) is a ribonucleoprotein comprising fusion RNA which is obtained by fusing a subject RNA and RNA which forms a composite with the RNA binding protein; (2) a step for detecting a signal caused by the marker protein, which expresses a function by means of the first element and the second element being in close proximity; and (3) a step for determining the interaction of the subject protein and the subject RNA by means of detecting the signal, wherein if the subject protein and the subject RNA interacted, the first fusion protein and the ribonucleoprotein form a composite, and the marker protein function is expressed by means of the first element and the second element being in close proximity.
3.WO/2021/011507ADAPTIVE ORDER FULFILLMENT AND TRACKING METHODS AND SYSTEMS
WO - 21.01.2021
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
 Appl.No PCT/US2020/041862 Applicant TEMPUS LABS Inventor JAROS, Charles
A genomic test processing system and method employ an order management engine and one or more order processing engines, the order processing engines including a receiving engine, an execution engine, and a broadcasting engine. The receiving engine receives a state of an order from the order management engine. The execution engine determines a sequence of steps to advance the received state of an order to a final state, iteratively designates each step of the sequence of steps as completed before initiating the next step of the sequence of steps, and advances the state of the order to a final state when a last step of the sequence of steps is completed. The broadcasting engine broadcasts the final state of the order to the order management engine. The order management engine causes one of the order processing engines to generate a next-generation sequencing report from the final state of the order.
4.WO/2021/011482METHOD TO ISOLATE TCR GENES
WO - 21.01.2021
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
 Appl.No PCT/US2020/041824 Applicant NEOGENE THERAPEUTICS B.V. Inventor SCHUMACHER, Antonius, Nicolaas, Maria
The present disclosure provides methods to recover repertoires of T cell receptors (TCRs). In some embodiments, TCR repertoires are recovered from non-viable samples. In some embodiments, libraries of TCRaβ pairs are created. In some embodiments, the methods disclosed are used for cancer immunotherapy or diagnostic purposes. Described herein, in some embodiments, are methods of identifying nucleotide sequences encoding T cell receptor a (TCRα)- and TCRβ-chains from a combinatorial library of nucleic acids.
5.WO/2021/010446METHOD FOR DETECTING MACROLIDE-ANTIBIOTIC-RESISTANT MUTANT BACTERIUM
WO - 21.01.2021
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/JP2020/027721 Applicant KAWASAKI GAKUEN EDUCATIONAL FOUNDATION Inventor TANAKA Yuhei
The present invention relates to a method for detecting a macrolide-antibiotic-resistant mutant bacterium, which comprises detecting two adenine point mutations, to each of which a macrolide antibiotic can bind, in a V-region in 23SrRNA domain in the macrolide-antibiotic-resistant mutant bacterium by an amplification reaction by PCR amplification.
6.WO/2021/011211A THERMOCYCLING PCR CHIP MADE OF TRANSPARENT GRAPHENE CONDUCTIVE FILM
WO - 21.01.2021
Int.Class C12Q 1/686
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6844Nucleic acid amplification reactions
686Polymerase chain reaction
 Appl.No PCT/US2020/040848 Applicant ZHU, Guozhi Inventor ZHU, Guozhi
In the present invention, graphene Transparent Conductive Film (TCF) is integrated into a disposable PCR chip in which PCR reaction containers are sandwiched by two graphene TCFs. PCR is performed by thermocycling of the on-chip two graphene TCF simultaneously. A temperature sensor in the PCR chip is to measure the chip temperature in a real-time manner during PCR reaction, and to provide a feedback to control the thermocycling of the graphene TCF.
7.WO/2021/009185PRIMERS FOR ISOTHERMAL AMPLIFICATION
WO - 21.01.2021
Int.Class C12Q 1/6827
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6827for detection of mutation or polymorphism
 Appl.No PCT/EP2020/069920 Applicant NATIONAL UNIVERSITY OF IRELAND, GALWAY Inventor HIGGINS, Owen
The present invention relates to primers for isothermal amplification, in particular primers for loop-mediated isothermal amplification (LAMP). Also disclosed are methods for identifying a target nucleic acid, and methods for identifying a nucleic acid modification or substitution of a target nucleic acid. The invention finds utility in the diagnosis of diseases or disorders.
8.WO/2021/011435METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES
WO - 21.01.2021
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/US2020/041740 Applicant MAGNANI, John L. Inventor MAGNANI, John L.
Cancer patients that express high levels of the E-selectin ligand (sialyl Lea/x) on their tumors have a poorer outcome. Interestingly, relapsed/refractory acute myeloid leukemia (AML) patients expressing high levels of sialyl Lex on their blasts show the greatest therapeutic response when treated with the E-selection inhibitor compound of Formula I. Transcriptome profiling of E-selectin ligand-forming glycosylation genes showed that ST3GAL4 and FUT7 were consistently expressed in the majority of cancers evaluated. Poor survival outcomes of FLT3-mutated AML patients that express high levels of ST3GAL4 and FUT7 implicated E-selectin in this disease state. These genes may be predictive biomarkers in AML patients. Methods of treatment of cancer comprising screening AML patients for expression of genes that contribute to the synthesis of the E-selectin ligand sialyl Lex, then treating those patients with an E-selection inhibitor, are disclosed.
9.WO/2021/009184NON-INVASIVE METHOD FOR THE DIAGNOSIS OR SCREENING OF COLORECTAL CANCER AND/OR PRE-CANCEROUS STAGE THEREOF
WO - 21.01.2021
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/EP2020/069918 Applicant INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER (IDIBAPS) Inventor CASTELLS GARANGOU, Antoni
Non-invasive method for the diagnosis or screening of colorectal cancer and/or pre-cancerous stage thereof. The present invention refers to an in vitro method for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof.
10.WO/2021/010534NOVEL DNA APTAMER AND USE THEREOF
WO - 21.01.2021
Int.Class C12N 15/115
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
 Appl.No PCT/KR2019/008987 Applicant NATIONAL CANCER CENTER Inventor KIM, Yun Hee
The present disclosure relates to a novel DNA aptamer and a use thereof and, specifically, to a DNA aptamer selected as specifically binding to cancer cells from a DNA library obtained by the Cell-SELEX method. The DNA aptamer selected and optimized as having a high binding ability to cancer, of the present disclosure, improves target cell and tissue targeting efficiency, and can be effectively used for cancer diagnosis, etc.
# -